Search

everythinglearnresearchcommunity

for

Search:↓

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.

A 23 year old male's 9-month progress with 1mg/day of finasteride, which has been life changing and resulted in a significant improvement in hair thickness.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

A user shared their experience with Finasteride for hair loss, noting improvement but still some thinning. They plan to get a hair transplant to address remaining thin spots and strengthen their hairline.

The user had a hair transplant in Turkey and started taking finasteride to maintain hair growth. They are satisfied with the results and plan to continue using finasteride while being cautious about hairstyles to prevent traction alopecia.

The user is asking for opinions on whether their hair growth is due to Pantostin and hormone treatments. One commenter confirms regrowth and asks about the hormone treatments.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

User is considering switching from finasteride to dutasteride and adding pyrilutamide for hair loss treatment. Other users recommend dutasteride for its effectiveness and suggest adding pyrilutamide.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

A 38-year-old man from Poland, balding for 15 years, shared his hair regrowth progress after 4 months of using finasteride (fin), minoxidil (min), micro-needling, and infrared light treatments. He recently switched from finasteride to dutasteride.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.

The user is experiencing hair loss and is using treatments like finasteride, minoxidil, and hormone replacement therapy (estradiol enanthate injections) to address it. They are advised to be patient with the treatments and consider using a dermapen for microneedling.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

The conversation is about hair loss treatment progress using a combination of 0.1% finasteride, 0.025% tretinoin solution, and 2.5mg oral minoxidil. Users express positive reactions and hope for similar results.

A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.